Description: Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
Home Page: www.simcere.com
No. 699-18, Xuanwu Road
Nanjing,
210042
China
Phone:
86 25 8556 6666
Officers
| Name | Title |
|---|---|
| Mr. Jinsheng Ren | Co-Founder, Chairman & CEO |
| Mr. Renhong Tang Ph.D. | Co-CEO & Exec. Director |
| Mr. Yushan Wan | CFO, Joint Company Sec. & Exec. Director |
| Mr. Quanfu Feng | VP of Marketing |
| Dr. Kevin Oliver Ph.D. | Sr. VP |
| Dr. Bijoyesh Mookerjee M.D. | Chief Medical Officer of Oncology |
| Mr. Danny Chen Ph.D. | Senor VP |
| Andrew Zhu | Sr. VP |
| Dr. Tamas Oravecz Ph.D. | Sr. VP & Chief Scientific Officer of U.S. |
| Song Wenjie | Sr. VP |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 22.1729 |
|---|---|
| Trailing PE: | 30.3556 |
| Price-to-Book MRQ: | 4.0973 |
| Price-to-Sales TTM: | 4.8255 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6542 |